89bio Shares Up 10% Since Q4 Earnings Announcement 
<p><a href='https://financialmodelingprep.com/financial-summary/ETNB'>89bio, Inc. (NASDAQ:ETNB)</a> shares rose more than 10% since the company’s reported Q4 results on Friday. R&D came in at $19.1 million and SG&A was $6.3 million. Cash and equivalents ended the quarter at $188.2 million. The company reiterated the March timeline for key ph.IIb pegoza NASH data. </p>
<p>Analysts at RBC Capital said they expect similar data to AKRO's FGF21 analog and believe this will lead to a meaningful stock upside. According to the analysts, pivotal studies in SHTG, an underappreciated opportunity with a low-risk path, remain on track and provide a high valuation floor. The analysts continue to see an attractive buying opportunity into the upcoming data.</p>

NASDAQ:ETNB